Patent intelligence · US
US 2024327366
POLYMORPH FORM OF PITOLISANT HYDROCHLORIDE
POLYMORPH FORM OF PITOLISANT HYDROCHLORIDE
Patent details — US 2024327366
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 3, 2024
- Expiration
- Sep 28, 2044
- Applicant
- BIOPROJET PHARMA [FR]
- CPC classes
- A61K 31/ 4453 A I, A61K/314453, A61P/2500, A61P/4300
Quick answer
US 2024327366 (POLYMORPH FORM OF PITOLISANT HYDROCHLORIDE) is held by BIOPROJET PHARMA [FR]. Status: granted. Granted Oct 3, 2024. Expires Sep 28, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BIOPROJET PHARMA [FR]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 4453 A I, A61K/314453, A61P/2500, A61P/4300
More from BIOPROJET PHARMA [FR]
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 2024327366?
US 2024327366 (POLYMORPH FORM OF PITOLISANT HYDROCHLORIDE) is held by BIOPROJET PHARMA [FR]. Status: granted. Granted Oct 3, 2024. Expires Sep 28, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 2024327366?
BIOPROJET PHARMA [FR] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 3 pharmaceutical patents for this assignee.
When does US 2024327366 expire?
Our index shows an expiration date of Sep 28, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.